Key result
Hospital Readmissions Reduction Program is not linked to meaningful delays in 30-day readmissions.
Why the study?
The impact of the Hospital Readmissions Reduction Program on timing of readmissions around the 30-day postdischarge penalty threshold was uncertain.
Observational (n=69,826,110)
Yes
Answers are grounded in this paper and cite their sources.
HRRP shows no clinically relevant readmission delays; leaves open broader quality effects in observational data.
BACKGROUND: The Hospital Readmissions Reduction Program (HRRP) initially penalised hospitals for excess readmission within 30 days of discharge for acute myocardial infarction (AMI), congestive heart failure (CHF) or pneumonia (PNA) and was expanded in subsequent years to include readmissions for chronic obstructive pulmonary disease, elective total hip arthroplasty, total knee arthroplasty and coronary artery bypass graft surgery. We assessed whether HRRP was associated with delays in readmissions from immediately before the 30-day penalty threshold to just after it. METHODS: We included Medicare fee-for-service beneficiaries discharged between 1 January 2007 and 31 October 2015. Readmissions were assessed until December 31, 2015. The study period was divided into three phases: January 2007 to March 2009 (pre-HRRP), April 2009 to September 2012 (implementation) and October 2012 to December 2015 (penalty). We estimated additional readmissions between postdischarge days 31-35 compared with days 26-30 using a negative binomial difference-in-differences model, comparing target HRRP versus non-HRRP conditions at the same hospital in the same month in the pre-HRRP and penalty phases. RESULTS: HRRP was not associated with a significant difference in AMI readmissions between postdischarge days 31-35 versus postdischarge days 26-30 for each hospital in the penalty phase, as compared with non-HRRP conditions and the pre-HRRP phase (p=0.19). There were statistically significant increases in readmissions CHF (0.040%, 95% CI 0.024% to 0.056%, p<0.01), PNA (0.022%, 95% CI 0.002% to 0.042%, p=0.03) and stroke (0.035%, 95% CI 0.010% to 0.060%, p<0.01); however, these readmissions represent <0.01% of readmissions during this time period. CONCLUSION: We did not identify consistently significant associations between HRRP and delayed readmissions, and importantly, any findings suggesting delayed readmissions were extremely small and unlikely to be clinically relevant.
No takes yet. Share an insight, caveat, or question.
Nathan et al. (2020) conducted an observational in Acute myocardial infarction, congestive heart failure, pneumonia (n=69,826,110). Hospital Readmissions Reduction Program (HRRP) vs. Pre-HRRP phase and non-HRRP conditions was evaluated on Difference in AMI readmissions between postdischarge days 31-35 versus days 26-30 (difference-in-differences) (-0.017% change, 95% CI -0.042 to 0.008, p=0.19). The Hospital Readmissions Reduction Program was not associated with clinically relevant delays in readmissions beyond post-discharge day 30, with changes in readmissions being extremely small (e.g., -0.017% for AMI, p=0.19).
Synapse has enriched 10 related papers. Consider them for comparative context: